{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-092522","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.516911+00:00","generated_at":"2026-06-04T00:05:09.303233+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks","bullets":["Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.","No ≥ Grade 3 non-hematologic treatment-related adverse events; well tolerated with no dose reductions.","ELVN-001 at ≥40mg QD shows superior target coverage vs 2nd-gen TKIs; PK supports once-daily dosing with no food effect.","89% of all enrolled patients remain on study; maximum tolerated dose not yet identified.","Company hosting virtual event with key opinion leaders at 8:00 AM ET today to discuss data."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-092522","json":"https://secwatch.observer/filing/0001193125-24-092522.json","markdown":"https://secwatch.observer/filing/0001193125-24-092522.md","text":"https://secwatch.observer/filing/0001193125-24-092522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312524092522/0001193125-24-092522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312524092522/d763719d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:05:09.303233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}